PCT Ltd (PCTL)

[aandt]

Found a document with some details from the UK, helps fill in some blanks on the timeline as well. Also supports the PCT story of events- These are minutes from NHS meetings, the one of interest is from March 2022 (page 46 of this pdf) These minutes were published by the NHS in May 2022.

This again shows that PCT has been engaged with the process all along, just as they have told us.

And as for the recent speculation of a sudden change... once again nothing to support that claim, all documentation shows that the PCT Annihilyzer is the machine engaged in the testing by NTH Solutions.

https://www.nth.nhs.uk/content/uploads/2022/05/Council-of-Governors-papers-5-May-22-FINAL.pdf

ICC Cleaning System Presentation
Tony Wilson, Innovation & Commercial Manager and Rebecca Denton-Smith
Lead Nurse Infection & Prevention Control, delivered a presentation on the
Pathisol PCT Annihilyzer Hospital system. Pathisol is a hospital made
disinfectant and cleaning product, used by the NHS Deep Cleaning and
Advisory Service. The product is an Eco friendly and organic cleaning product
non-toxic disinfectant stronger than bleach. Pathisol PCT Annihilyzer produces
a solution, Hypochlorous Acid (HOCI) which Is produced by white blood cells
totally safe to human cells. The system is a new innovative solution to the UK
market so no reference to existing public health guidance however requires a
UK study reference site. North Tees and Hartlepool Foundation Trust is a potential launch site for the NHS, exclusive to NTH Solutions. TW explained that
Pathisol is an anagram for Hospital due to this product manufactured at the
University Hospital of Hartlepool.
The system, was developed in the US and effectively rolled out across twelve
US hospitals. Demonstrating a significant reduction in reported Healthcare
Associated Infection (HAI’s) as well as raising cleaning standards since 2016.
NTH Solutions agreed to evaluate Annihilyzer system with the PCT Health and
Project Team with North Tees & Hartlepool Foundation Trust in October 2019
with a delivery to North Tees Hospital in November 2019.
TW explained it was agreed to proceed with the site based swab testing and
provide solution evidence testing. In March 2020 HOCL Solution sent for testing
to 20/30 Labs for BS/EN efficiency. In May 2020, an Independent microbiologist
presented a report from Teesside University. It was agreed to commence a
Ward trial at Holdforth Unit in June 2020 for 8-weeks, an extension was
proposed to 6 busy wards at North Tees however, this was paused due to
COVID. A new date commenced from March 2021– July 2021 to evaluate the
product on 6 Wards. Feedback from the staff was very positive with reductions
in HAI’s, reducing the daily bacteria count present. A trial period was carried out
through NIHR with the appointed Chief Investigating Office Andrew Ward –
NTHFT Microbiology supported by Infection Prevention Control Lead Nurse,
Rebecca Denton-Smith.
TW confirmed an independent academy; the Horizon Centre at Teesside
University was to conduct swab testing. A research study paper was produced
in October 2021 on results found by operating the system on Wards.
An additional 3 Ward study was required in November 2021 with visitors to be
present however, this was paused due to the restrictions on visitors due to
COVID-19.
TW explained at present since the trial finished in July 2021, Pathisol had been
in operation for cleaning on 3 occasions where outbreaks had occurred with the
elimination of the outbreak.
TW reported that a 50% reduction in the number of reported cases on the 6
wards in the first 3 months of the trial.
TW confirmed a study is to be finalised in July 2022 with the trial published
Nationally as a NHS research Study.
No NHS Hospital has implemented HOCL as its cleaning solution of choice at
present.
Discussions ensued amongst the committee on staff training regarding the
usage of the solution, storage and the anticipated effectiveness of the cleaning
product.
The Chair confirmed a full business case would be presented to the Board
based on ICP evidence, cost improvement, performance of solution and
sustainability benefits considered with the governors kept in touch on progress.